INVESTING IN BIOMEDICAL DISCOVERIES

LASCCO SA is a biomedical-technology development private company based at the Biopole of Lausanne, Switzerland.

The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.

The company’ portfolio is currently composed of two critical care products based on innovative technologies and aiming at fighting sepsis and treating severe bacterial and viral infections.

LATEST NEWS

LASCCO and Abionic Announce a Licensing Agreement with Fapon for PSP Sepsis Test in China.
October 26, 2023

Combioxin’s licensee, Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a first-in-class anti-virulence agent for the treatment of severe pneumonia.
November 14, 2022

MEET THE TEAM

Samareh Azeredo da Silveira

Managing Director

Frédéric Lajaunias

Managing Director

Toni Perez

Chief Medical Director

CONTACT US